Product
Elinzanetant
Aliases
Elinzanetant (BAY3427080)
12 clinical trials
9 indications
Indication
Hot FlashesIndication
Hormone-receptor Positive Breast CancerIndication
Sleep DisturbancesIndication
Vasomotor SymptomsIndication
Healthy Control ParticipantsIndication
MenopauseIndication
Night WakingClinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal WomenStatus: Completed, Estimated PCD: 2023-07-25
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 52 Weeks in Postmenopausal WomenStatus: Completed, Estimated PCD: 2023-03-29
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for Additional 2 Years in Women With Hormone-receptor Positive Breast Cancer:Status: Active (not recruiting), Estimated PCD: 2024-01-29
Clinical trial
A Randomized, Parallel-group Treatment, Phase 2, Double-blind Pilot Study to Investigate the Efficacy and Safety of Elinzanetant Compared With Placebo for Treatment of Sleep Disturbances Associated With Menopause.Status: Recruiting, Estimated PCD: 2024-10-15
Clinical trial
A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Over 26 Weeks in Postmenopausal WomenStatus: Completed, Estimated PCD: 2023-06-13
Clinical trial
A Randomized, Double-blind, Placebo- and Active-controlled, 4-period, Crossover Study to Investigate Effects of Elinzanetant on Simulated Driving Performance and Cognitive Function in Healthy WomenStatus: Completed, Estimated PCD: 2024-04-15
Clinical trial
A Double-Blind, Randomised, Placebo Controlled, Adaptive Design Study of the Efficacy, Safety and Pharmacokinetics of NT-814 in Female Subjects With Moderate to Severe Vasomotor Symptoms Associated With the MenopauseStatus: Completed, Estimated PCD: 2019-11-21
Clinical trial
Single Center, Randomized, Open-label, Cross-over Study to Investigate the Pharmacokinetics of Two Oral Formulations of Elinzanetant After Single Dosing in Healthy ParticipantsStatus: Completed, Estimated PCD: 2021-06-01
Clinical trial
Open-label, Fixed Sequence Crossover Study to Determine the Effects of a Single Dose of Elinzanetant (BAY 3427080) on the Pharmacokinetics of Dabigatran Etexilate in Healthy ParticipantsStatus: Completed, Estimated PCD: 2022-09-20
Clinical trial
Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Elinzanetant in Participants With Impaired Renal Function in Comparison to Matched Controls With Normal Renal FunctionStatus: Completed, Estimated PCD: 2022-10-19
Clinical trial
A Randomized, Double-blind, Placebo- and Moxifloxacin-controlled Study to Investigate the Safety and Pharmacokinetics of Single Ascending Supratherapeutic Doses of Elinzanetant in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-02-07
Clinical trial
Open-label, One-sequence Crossover Study to Determine the Effects of Multiple Doses of Elinzanetant on the Pharmacokinetics of Rosuvastatin in Healthy ParticipantsStatus: Completed, Estimated PCD: 2021-07-23